Drug Profile


Alternative Names: HCP0912; Irbesartan/atorvastatin; Irbestin; Rovelito

Latest Information Update: 26 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Sanofi
  • Class Antihyperlipidaemics; Biphenyl compounds; Fatty acids; Heart failure therapies; Heptanoic acids; Pyrroles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 31 Dec 2013 Launched for Hyperlipidaemia in South Korea (PO)
  • 31 Dec 2013 Launched for Hypertension in South Korea (PO)
  • 08 Nov 2013 Registered for Hyperlipidaemia in South Korea (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top